Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16(10):1297–313.
Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8(2):96–104.
Llibre JM, Young B. Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance. HIV Med. 2014;15(4):193–5.
Martin DA, Luz PM, Lake JE, Clark JL, Veloso VG, Moreira RI, Cardoso SW, Klausner JD, Grinsztejn B. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997–2011. BMC Infect Dis. 2014;14:322.
Kaufmann GR, Elzi L, Weber R, Furrer H, Giulieri S, Vernazza P, Bernasconi E, Hirschel B, Battegay M. Swiss HIVCS: interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS. 2011;25(4):441–51.
Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1–15.
Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69(1):98–108.
Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298.
Nsanzimana S, Binagwaho A, Kanters S, Mills EJ. Churning in and out of HIV care. Lancet HIV. 2014;1(2):e58–9.
World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2010. p. 1–156.
Lynen L. Clinical HIV/AIDS care guidelines for resource-poor settings. 2nd ed. Brussels: Medecins Sans Frontieres Operational Centre; 2006.
WHO. Consolidated strategic information guidelines for HIV in the health sector. Geneva: World Health Organization; 2015.
Standard operating procedures Medecins Sans Frontieres Ethics Review Board. http://www.fieldresearch.msf.org/msf/bitstream/10144/294968/5/MSFERBSOPDec2013.pdf. Accessed 23 Sept 2015.
Kavasery R, Galai N, Astemborski J, Lucas GM, Celentano DD, Kirk GD, Mehta SH. Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr. 2009;50(4):360–6.
Moore DM, Zhang W, Yip B, Genebat M, Lima VD, Montaner JS, Hogg RS. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11(5):299–307.
Ahonkhai AA, Banigbe B, Adeola J, Onwuatuelo I, Bassett IV, Losina E, Freedberg KA, Okonkwo P, Regan S. High rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in Nigeria. BMC Infect Dis. 2015;15:397.
Nacher M, El Guedj M, Vaz T, Nasser V, Randrianjohany A, Alvarez F, Sobesky M, Magnien C, Couppie P. Risk factors for follow-up interruption of HIV patients in French Guiana. Am J Trop Med Hyg. 2006;74(5):915–7.
Vinikoor MJ, Joseph J, Mwale J, Marx MA, Goma FM, Mulenga LB, Stringer JS, Eron JJ, Chi BH. Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia. AIDS Res Hum Retroviruses. 2014;30(10):949–55.
Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi V, Alwar T, Casalini C, Elul B. High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care. AIDS. 2014;28(4):559–68.
Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K, Collaboration C. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr. 2006;42(5):554–61.
Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, Bekker LG, Wood R. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55(3):e17–23.
Ahonkhai AA, Noubary F, Munro A, Stark R, Wilke M, Freedberg KA, Wood R, Losina E. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012;7(3):e32993.
Mills EJ, Funk A, Kanters S, Kawuma E, Cooper C, Mukasa B, Odit M, Karamagi Y, Mwehire D, Nachega J, et al. Long-term health care interruptions among HIV-positive patients in Uganda. J Acquir Immune Defic Syndr. 2013;63(1):e23–7.
Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, Calmy A, Bernasconi E, Vernazza P, Weber R, et al. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr. 2013;64(5):472–8.
Murphy K, Hoover DR, Shi Q, Cohen M, Gandhi M, Golub ET, Gustafson DR, Pearce CL, Young M, Anastos K. Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS. 2013;27(15):2413–23.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS Patient Care STDs. 2015;29(3):111–6.
Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr J AIDS Res. 2010;9(2):117–24.
Samji H, Taha TE, Moore D, Burchell AN, Cescon A, Cooper C, Raboud JM, Klein MB, Loutfy MR, Machouf N, et al. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med. 2015;16(2):76–87.
May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, Keiser O, Sterne JA, Dabis F, Egger M, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376(9739):449–57.
Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, Thorlund K, Negin J, Lester R, Yaya S, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27(3):417–25.
Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, Rasschaert F, Biot M, Laga M. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014;19(5):514–21.
Weigel R, Estill J, Egger M, Harries AD, Makombe S, Tweya H, Jahn A, Keiser O. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS. 2012;26(3):365–73.
Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, Yiannoutsos CT, Owiti M, Kimaiyo S, Braitstein P. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88(9):681–8.
Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, MacKeen L, Haberer J, Kimaiyo S, Sidle J, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(6):825–34.
Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838–45.
Haberer JE, Musiimenta A, Atukunda EC, Musinguzi N, Wyatt MA, Ware NC, Bangsberg DR. Short message service (SMS) reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda. AIDS. 2016;30(8):1295–300.
Strategies for Management of Antiretroviral Therapy Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.
Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and mortality amongst adults lost to follow-up in ART programmes in low- and middle-income countries: systematic review and meta-analysis. Trop Med Int Health. 2015;20(3):365–79.
Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790.
Taffe P, Rickenbach M, Hirschel B, Opravil M, Furrer H, Janin P, Bugnon F, Ledergerber B, Wagels T, Sudre P, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16(5):747–55.